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Abstract
In recent years, mGlu4 has received great attention and research effort because of the potential 
benefits of mGlu4 activation in treating numerous brain disorders, such as Parkinson’s disease 
(PD). Many positive allosteric modulators of mGlu4 have been developed. To better understand 
the role of mGlu4 in healthy and disease conditions, we are interested in developing an mGlu4 
selective radioligand for in vivo studies. Thus, we had synthesized and studied [11C]2 as a PET 
tracer for mGlu4, which demonstrated some promising features as a PET radioligand as well as the 
limitation need to be improved. In order to develop an mGlu4 ligand with enhanced affinity and 
improved metabolic stability, we have modified, synthesized and evaluated a series of new N-
phenylpicolinamide derivatives. The SAR study has discovered a number of compounds with low 
nM affinity to mGlu4. The dideuteriumfluoromethoxy modified compound 24 is identified as a 
very promising mGlu4 ligand, which has demonstrated enhanced affinity, improved in vitro 
microsomal stability, good selectivity and good permeability.
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L-Glutamate is the most abundant excitatory neurotransmitter in the CNS (Central nerve 
system) of vertebrates and probably mediates more than 50% of all synapses.1,2 Two major 
classes of receptors, mGlu and iGlu, are involved in glutamate signal transfer. The mGlu 
belong to Class C of the GPCR (G protein-coupled receptor) super family, which are 
thought to exist as dimers and have a distinct large extracellular N-terminus. This 
extracellular N-terminal domain contains two hinged globular domains referred as the Venus 
Flytrap Domain (VFD), which is the orthosteric binding site for the endogenous ligand, L-
glutamate.3 The mGlu can be further divided into three subgroups including eight known 
receptor subtypes (group I: mGlu1 and mGlu5, group II: mGlu2 and mGlu3, and group III: 
mGlu4, mGlu6, mGlu7 and mGlu8) based on their structural similarity, ligand specificity, 
and preferred coupling mechanisms.4 The mGlu are involved in glutamate signaling in 
almost every excitatory synapse in CNS, and they have distinctive biodistribution in CNS 
depending on subtypes and subgroups.5 In recent years, mGlu4 has received great attention 
and research effort because of the potential benefits of mGlu4 activation in treating 
numerous brain disorders, such as Parkinson’s disease (PD).6,7 As a group III mGlu, mGlu4 
interacts with the Gαi/o subunit of G-protein which negatively couples with adenylate 
cyclase to inhibit cAMP dependent signal pathways.8,9 The mGlu4 is expressed at multiple 
synapses throughout the basal ganglia, mainly localized presynaptically and expressed in the 
striatum, hippocampus, thalamus, and cerebellum.4,10,11 Its activation reduces 
neurotransmitter release, a mechanism implicated in the pathophysiology of PD. The 
activation of the mGlu4 receptor can be accomplished by two different mechanisms: 
orthosteric agonists (competing with L-glutamate) or noncompetitive positive allosteric 
modulators (PAMs). Most orthosteric ligands of mGlu4 made in the past lack clear subtype 
selectivity and BBB (Blood-brain barrier) penetration, but notable examples exist of 
selective and brain penetrant orthosteric agonists, such as LSP4-2022.12,13 Much recent 
effort has been focused on the development of allosteric modulators, which target the seven-
transmembrane spanning domain. In particular, the allosteric modulation of mGlu4 has 
spurred intense interest after (−)-PHCCC (1, N-phenyl-7-(hydroxyimino)-
cyclopropa[b]chromen-1a-carboxamide), a partially selective mGlu4 PAM, was discovered 
and demonstrated activity in models of neuroprotection and PD. Since then there has been 
substantial progress in identifying PAMs for mGlu4.6,14,15 Figure 1 shows some 
representative mGlu4 PAMs.6,14,16,17,18,19,20 Subsequent results with PAMs of mGlu4 have 
further validated the antiparkinsonian activity in animal models of PD,11,17,21,22,23,24 in 
which this approach has opened a new avenue for developing nondopaminergic treatments 
for PD and for identifying a novel disease modifying therapeutics.
To better understand the role of mGlu4 in healthy and disease conditions, we are interested 
in developing an mGlu4 selective radioligand for in vivo study. As a noninvasive medical 
imaging technique and a powerful tool in neurological research, positron emission 
tomography (PET) offers a possibility to visualize and analyze the target receptor expression 
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under physiological and pathophysiological conditions. PET is being applied more often to 
detect disease-related biochemical changes before the disease-associated anatomical changes 
could be found by standard medical imaging modalities. Moreover, PET tracers serve as 
invaluable biomarkers during the development of potential therapeutic drugs. Thus, 
extensive research efforts have been directed toward the development of PET radioligands 
suitable for probing mGlu such as mGlu1 and mGlu5.15
Recently, we have reported a carbon-11 labeled PET ligand [11C]2 (N-(4-Chloro-3-
[11C]methoxyphenyl)picolinamide)25, which was based on a reported mGlu4 PAM 216. In 
2009, two research groups at Addex Pharma26 and Vanderbilt University16 have 
independently disclosed a series of small arylamide compounds as a new class of mGlu4 
PAMs. Engers et al. found from a high-throughput screening there were a number of small 
arylamide compounds having mGlu4 PAM activity. They reported the SAR study, in vitro 
pharmacokinetic (PK) parameters and in vivo rat PK, which included the SAR results for 
sixteen N-phenylpicolinamide derivatives.16 Compounds 2 and 3 were the most potent 
mGlu4 PAMs in this series and showed some potentially suitable properties for PET tracer 
development, which include: 1) Rapid penetration into rat brain following intraperitoneal 
injection (Tmax for brain: 0.5 h); 2) High brain:plasma (B/P) partition coefficients for both 
compounds (B/P=4.1 for 2 and 9.9 for 3), in which B/P was determined by 
AUC0–8h, Brain/AUC0–8h, Plasma; 3) Good in vitro potency and efficacy for both human and 
rat mGlu4 compared to previous reported mGlu4 PAM; 4) Good selectivity over other mGlu 
subtypes; 5) Compound 2 was the first mGlu4 PAM to demonstrate efficacy in a preclinical 
rodent model of motor impairments associated with PD.6 Thus, we had synthesized and 
studied [11C]2 as a PET tracers for mGlu4. This compound demonstrated some promising 
features as a PET radioligand such as the fast uptake into brain and the specific 
accumulation in mGlu4-rich regions of the brain. However, in comparison to one of the best 
mGlu5 PET tracer [18F]FPEB (3-[18F]fluoro-5-(2-pyridinylethynyl)benzonitrile)27,28, [11C]2 
showed the decreased retention time in the brain, which may affect the quality of the 
imaging. The results indicate that the affinity and metabolic stability of this class of tracers 
need further optimization. We report here the synthesis and structure-affinity relationship 
study of new N-phenylpicolinamide derivatives to develop mGlu4 ligands with improved 
affinity and metabolic stability.
We have modified and synthesized a series of new N-phenylpicolinamide derivatives for 
SAR study, in which the syntheses are shown in Scheme 1 – 3 (see Supplementary data). 
Three most active known compounds in this series (2, 3, and 10) were also synthesized and 
evaluated as the reference compounds for optimization. On the basis of previous SAR 
results16, we modified compound 2 at three positions (3- or 4-phenyl, 6-pyrindyl) as 
illustrated in Figure 2. It is known that the SAR of this series was tight,6,16 so we started 
with minor modifications based on the reported data. As shown in Table 1, the modifications 
include the isosteric replacement of hydrogen by fluorine or deuterium, oxygen by sulfur, 
methoxy by cyano group and change for different halogen atoms. The radiolabeling strategy 
was also considered in lead optimization design to generate the facile labeling positions for 
either C-11 or F-18 tracer.
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Since poor BBB permeability and high nonspecific binding (NSB) are among the most 
frequent causes for failure in CNS PET ligand development, it is necessary to consider some 
important physicochemical parameter such as MW, ClogP and tPSA at the design stage. It 
has been recently proposed that more desirable ranges for CNS drugs are ClogP <3, MW < 
360 and 40 < tPSA < 90.29 As shown in Table 1, all compounds except 12 and 22 possess 
the favorable physicochemical parameters, making them ideal candidates for CNS ligand 
development.
The lead compounds 2 and 3 were identified as mGlu4 PAMs by using functional assays 
(calcium mobilization assays for human mGlu4 and thallium flux assays for rat mGlu4) and 
characterized with EC50, the maximum response and the fold shift values.16 It is known that 
the EC50 value may not always correlated closely to the affinity value for PAM.30 It is very 
important to study the binding affinity for developing PET ligands. Thus, we prepared the 
tritium-labeled compound 2 ([3H]2, N-(4-chloro-3-(methoxy-t3)phenyl)picolinamide) for 
competitive binding assay.31 The synthesized compounds were characterized with 
competitive binding studies using mGlu4 transfected CHO cells by increasing the 
concentration of test materials from 0.01 nM to 10 μM in presence of 2 nM of [3H]2, in 
which the binding affinities to mGlu4 were described as IC50 values (Table 1).32
In structure-affinity study, we first evaluated the substitutions at the 4-phenyl position by 
keeping the 3-methoxy group constant. The 4-phenyl position of N-phenylpicolinamide was 
tolerated with some substitutions as demonstrated in known compounds 6–8, in which 
compounds 6 and 7 were reported very potent but poor brain penetration.20 Thus we limited 
the 4-phenyl substitutions for different halogens. The results show that the 4-chloro 
substitution give the best affinity, in which the affinity values of 2 and 10–13 are in the 
following order: Cl < H < F < I < Br. Larger halogen substitutions such as iodine and 
bromine led to substantial loss in affinity. It was then found that the 3-methylthio group was 
superior to the 3-methoxy group by comparing compounds 13 and 14, showing a 2.8 fold 
enhancement in affinity.
On the other hand, compounds 15–17 had been incorporated a fluorine atom at 6-pyrindyl 
position of N-phenylpicolinamide, which can have a relatively facile fluorine-18 labeling. 
Compared to 2 and 3, the affinity of 15 and 16 was not significantly reduced.
Next we turned our attention to the 3-phenyl position. It is considered that the metabolic 
stability was one of major issues for ML-128 (2), in which the 3-methoxy group was 
identified as the soft group. The 3-phenyl position was also very sensitive with substitutions. 
It was reported a simple change of 3-difluoromethoxy in compound 3 to 3-trifluoromethoxy 
group imparted a more than 10 fold loss of activity.16 Our initial effort was directed at 3-
cyano substitution, in which 11C-cyanation may be carried out through a palladium-
mediated cyanation or the Rousenmund-von Braun reaction.33 Five 3-cyanophenyl 
compounds (18–22) with different 4-phenyl substitutions were evaluated. The results show 
that the 3-cyano-4-chloro-analog 20 give a similar affinity compared to the 3-methoxy-4-
chloro-analog 2. The affinity values of 18–22 are depending on 4-phenyl substitution and in 
the following order: Cl < F < H < Br < I, which shows different substitution effect compared 
to 3-methoxy analogs 2 and 10–13. We then replaced 3-methoxy with 3-fluoromethoxy for 
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two reasons: first, since both 3-methoxy- and 3-difluoromethoxy-analogs exhibited the 
activity, fluoromethoxy should be also active; second, it generates a position for fluorine-18 
labeling. Fluorine-18 is often the radionuclide of choice for both its physical and nuclear 
characteristics. Its half-life is long enough to carry out relatively extended imaging protocols 
when compared to what is possible with carbon-11. This facilitates kinetic studies and high-
quality metabolic and plasma analysis. However, fluorine-18 labeling is normally limited to 
chemical structures already containing a fluorine atom and the possible labeling strategies 
are limited for the preparation of radiotracers of high specific radioactivity. The result shows 
that 3-fluoromethoxy compound 23 has an improved affinity (3.2 nM) compared to that (5.1 
nM) of 2, which improves 1.6 fold. However, 3-fluoromethoxy group may not be 
metabolically stable, since the 3-methoxy and 3-difluoromethoxy groups were metabolically 
unstable in compounds 2 and 3. On the other hand, 3-trifluoromethoxy analog of 3 was 
significantly more stable but lack activity.16 Hence, we had applied a 3-
dideuteriumfluoromethoxy group to replace 3-fluoromethoxy group as shown in compounds 
24 and 25. Deuterium isotope effects have been used to reduce in vivo metabolic rates. For 
example, Zhang et al. reported that a deuterium-substituted analog (with 18FD2CO) as a 
radioligand for peripheral benzodiazepine receptor (PBR) had remarkably prolonged the 
half-life (T1/2) in mice brain.34 The deuterium substitution may reduce the rate of 
defluorination initiated by cleavage of the C–H bond without altering the binding affinity to 
mGlu4. The result shows that the 3-dideuteriumfluoromethoxy modified compounds 24 and 
25 have excellent affinity.
On the basis of the affinity of these picolinamide derivatives, we subsequently determined 
the in vitro microsomal stability of the selected compounds that include 2–4 and 23–24 
(Table 2). Compound 4 (ADX88178) is one of a most potent mGlu4 PAM to date and was 
shown to be orally active in a number of preclinical in vivo PD models.14,22 As Table 2 
shows, the dideuteriumfluoromethoxy-compound 24 (T1/2 = 7.4 min) is more stable than the 
corresponding fluoromethoxy-analog 23 (T1/2 = 5.8 min) and the methoxy-analog 2(T1/2 = 
4.9 min). It was reported that the cleaving rate of the C–H bond wasabout 6.7 times faster 
than that of C–D bond at 25 °C.34 On the other hand, the half time and the difference of the 
metabolic rates of the dideuteriumfluoromethoxy analog and the fluoromethoxy analog 
depended on the level of the enzyme. In developing the PET ligand for PBR, Zhang et al. 
found that the half time (T1/2) in the plasma was 2.575 min for the deuterium-substituted 
analog (with 18FD2CO) and 2.367 min for the non-deuterated analog. However, the half 
time (T1/2) of the deuterium-substituted analog in the brain was >60 min, whereas that of for 
the non-deuterated analog was only 2.227 min.34 We anticipate that the difference of the 
half times in the brain between compounds 24 and 23 as well as 2 could be more significant. 
Compared to 4, compound 24 has the same affinity and a similar in vitro microsomal 
stability. It is clear that compound 24 has both enhanced affinity and improved in vitro 
microsomal stability compared to 2.
The selectivity of compound 24 was also determined among the various mGlu subtypes, in 
which the functional assays were carried out on mGlu1, mGlu2, mGlu5, mGlu6 and mGlu8. 
Compound 24 showed little activity against these mGlu (Supporting Information).
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In addition, the permeability values of 2–4 and 23 were measured using BBB PAMPA 
model at pH 7.4, which characterized the rate across the BBB due to passive diffusion. The 
determined effective permeability (Pe) values are summarized in Table 2, in which the Pe 
results for internal highly and low permeable standards are 160 for propranolol and <2.8 for 
atenolol, respectively. This result indicates that compounds 23 and 24 have good BBB 
permeability. Although high BBB passive permeability does not necessary translate to 
sufficient unbound drug concentration in the brain because of potential intrinsic clearance 
and efflux transport, it is beneficial for CNS drug candidates.
In summary, we have modified, synthesized and evaluated a series of new N-
phenylpicolinamide derivatives. Our research further demonstrated that N-
phenylpicolinamide is a good template to develop mGlu4 ligands, which has offered 
extensive SAR results by us and other labs.16,26 The SAR study has discovered a number of 
compounds with good affinities (<10 nM) to mGlu4. The dideuteriumfluoromethoxy 
modified compound 24 is identified as a very promising mGlu4 ligand, which has 
demonstrated enhanced affinity, improved in vitro microsomal stability, good selectivity and 
good permeability. Compound 24 is considered as an attractive candidate for future labeling 
with fluorine-18 as an mGlu4 PET tracer. Since a number of compounds have good affinity 
we are studying their PAM activity to mGlu4 and potential therapeutic applications.
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Some representative mGlu4 PAMs.
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Modificatons on compound 2
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Synthesis of the N-phenylpicolinamide derivatives.
Reagents and conditions: (a) for carboxylic acids, EDC.HCl, HOBt.H2O, DIPEA, dioxane; 
(b) for carboxylic acids, 1. thionyl chloride, benzene, reflux for 2 h; 2. TEA, THF, 40 °C, 1 
h; (c) for acid chloride, DIPEA, CH2Cl2, 4h.
Zhang et al. Page 11














Synthesis of the N-phenylpicolinamides 12 and 22.
Reagents and conditions: (a) (SnMe3)2, Pd(PPh3)4, Toluene, reflux, 8.5 h; (b) I2, CH2Cl2, 2 
h.
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Synthesis of the N-(3-fluoromethoxyphenyl)picolinamides 23 – 25.
Reagents and conditions: (a) Ag(OTs), MeCN, reflux, overnight; (b) CsF, HO(CH2O)6H, 
reflux, 3.5 h; (c) N-(4-R-3-hydroxyphenyl)picolinamide, K2CO3, 40–50 °C, 3 days.
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